Clinical Trials
42 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT06457997 2026-01-29
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1 Terminated
NCT05935748 2025-11-12
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Phase 2 Terminated
NCT04442126 2025-05-23
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Terminated
NCT04633278 2025-05-11
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT00051532 2025-02-25
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
LEO Pharma
Phase NA Terminated
NCT00051545 2025-02-25
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
LEO Pharma
Phase 3 Terminated
NCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT05001282 2024-08-07
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Phase 1/2 Terminated
NCT04816214 2024-03-05
GEOMETRY-E
Novartis
Phase 3 Terminated
NCT04441099 2023-09-07
NBE-002 in Patients With Advanced Solid Tumors
NBE-Therapeutics AG
Phase 1/2 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02437916 2022-11-08
Safety Study of AMG 228 to Treat Solid Tumors
Amgen
Phase 1 Terminated
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT00198315 2022-03-04
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 3 Terminated
NCT00198328 2022-03-04
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 3 Terminated
NCT03549338 2020-09-28
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Symphogen A/S
Phase 2 Terminated
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT02089334 2020-06-30
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Rexahn Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT03071809 2019-08-14
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
Lexent Bio, Inc.
Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT00403052 2019-04-16
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
Dynavax Technologies Corporation
Phase 1 Terminated
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated
NCT00417287 2018-05-16
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
Seagen Inc.
Phase 2 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00989092 2014-01-29
Darbepoetin Alfa and Anemia of Cancer
Amgen
Phase 2 Terminated
NCT00365183 2013-10-31
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Pharmacyclics LLC.
Phase 2 Terminated
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated
NCT01320020 2013-07-02
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Neovii Biotech
Phase 1 Terminated
NCT00816686 2013-02-27
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
Astellas Pharma Inc
Phase 1 Terminated
NCT01016054 2013-02-27
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Astellas Pharma Inc
Phase 1 Terminated
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT00100685 2012-04-27
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Abbott
Phase 2 Terminated
NCT00557596 2009-12-01
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
Aegera Therapeutics
Phase 1/2 Terminated
NCT00165633 2008-12-09
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
Eisai Inc.
Phase 2/3 Terminated
NCT00047632 2007-11-01
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
InterMune
Phase 3 Terminated